admin

TORONTO, ON / April 29, 2021 -- CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), an award-winning Life Science/Pharmaceutical company developing formulations combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced the filing of its International Patent, trade named Mentanine®, which has demonstrated at least 10-times (10X) the efficacy compared to Pharma Grade CBD. Mentanine® - an International CBD Excellence Award 2020 formulation was scientifically developed through preclinical trials at Western University. Results of its potential effect on anxiety, depression, PTSD, and schizophrenia have been statistically significant. Our evidence also found that this formulation targeted a specific nuclear cellular receptor involved in anti-inflammatory mechanisms indicating that this formula may also treat inflammatory disorders. [...]

TORONTO, ON / April 7, 2021 -- CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), an award-winning Life Science/Pharmaceutical company developing health and wellness products combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced that Rob Rinderman has joined CanaQuest as its new Director of Communications. Mr. Rinderman will focus on managing a proactive investor relations and corporate communications program, further expanding investor community and media awareness about the company's material corporate developments and future prospects. "We are delighted that a seasoned communications professional with decades of financial experience has agreed to join our team at this important time in our corporate evolution," stated CanaQuest President Paul Ramsay. "We believe adding a veteran like [...]

TORONTO, ON / March 30, 2021 -- CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced it has been awarded the International CBD Life Science R & D Excellence Award 2020 by Global Health & Pharma, United Kingdom, a global information sharing platform & multi-disciplinary members community. About Global Health & Pharma Awards: When it comes to handing out recognition and awards, we believe there are few more deserving than those whose dedication changes the lives of millions of people every day. Our awards recognize innovation and courage in all aspects of the healthcare and pharmaceutical [...]

CanaQuest Targeting Same Mental Health Space Where GW Pharma was Acquired for US$7.2B TORONTO, ON / March 23, 2021 -- CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that Fundamental Research Corp ("FRC"), one of the world's largest independent research houses, has launched coverage on CanaQuest with a BUY Rating. Its full report is available here: https://canaquest.com/wp-content/uploads/2021/03/CanaQuest-Research-Report-by-FRC-March-2021.pdf FRC has a 17-year track record of covering 550+ companies since inception. An excerpt from FRC's report is included below… "In conclusion, we believe the company's formulations have potential to generate demand based on their differentiating features. Even [...]

TORONTO, Feb. 02, 2021 — CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the “Company” or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), is pleased to announce its new partnership with the Canadian Cannabis Dispute Resolution Centre ("CCDRC"), a national organization that has developed cannabis-related education and training programs, both domestically and internationally, to assist different levels of government, the private sector, industry-specific organizations and associations.The CCDRC/CanaQuest partnership will serve to raise global awareness. The common theme of all education relates to conflict resolution, which can be mitigated through education. A critical component of the partnership will be its focus on promoting scientifically backed evidence, pre-clinical data [...]

TORONTO, Feb. 02, 2021 -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced a new production and distribution agreement with PurCann Pharma (“PurCann“) and SiliCycle Inc. (“SiliCycle“). PurCann, a subsidiary of SiliCycle, is recognized for its unique expertise in the Extraction-Purification and commercialization of cannabinoids. This agreement facilitates CanaQuest’s planned production, distribution and global export of Mentanine® and Mentabinol® formulations, through its wholly owned subsidiary, ADC BioMedical Corp, which was awarded a Cannabis Medical Sales, Import/Export License from Health Canada under the Cannabis Act. Initial sales are anticipated within 16 weeks after funding. Hugo St-Laurent, PurCann, [...]

TORONTO, Jan. 21, 2021 — CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), is pleased to release a recent interview with company Co-founder and President, Paul Ramsay, on The Wall Street Analyzer, a multi-media financial research and publishing company reporting to the investment community on publicly held companies. It can be heard in full at:https://wallstreetanalyzer.com/2020/12/23/canaquest-medical-corp-otc-canqf/Highlights in the discussion include significant milestones achieved by the Company:The Announcement that The Journal of Neuroscience has published the findings of Western University’s research leading to the discovery of Mentabinol®, a patented THC based formulation & L-theanine - a safer alternative, for people who are taking THC for mental [...]

TORONTO, Dec. 03, 2020 -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that The Journal of Neuroscience has published the findings of Western University’s research leading to the discovery of the Mentabinol®, a patented THC based formulation & L-theanine, a compound derived from Green Tea leaves. The Journal of Neuroscience, a world leading research publication, is a weekly peer-reviewed scientific journal published by the Society for Neuroscience. It covers empirical research on all aspects of neuroscience. This research showed that when the THC based formulation was combined with the compound L-theanine it protected [...]

TORONTO – September 17, 2020 − CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that it has been approved to raise capital on The OCMX™, an online portal that publicizes and provides financial connections to public and privately held investment opportunities. Planned use of proceeds for CanaQuest’s raise include helping further facilitate a funding pathway for FDA drug approval, which is already underway. The OCMX™ has spent considerable time completing its due diligence on the Company and concluded that there is indeed a tremendous opportunity for Investors and Advisors. The OCMX™ noted that, “CanaQuest [...]

TORONTO – July 14, 2020 − CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a company developing unique health products and nutraceuticals utilizing cannabis/hemp molecules and botanical compounds, has filed a Provisional Cannabidiol/Omega-3 Patent, trade named Mentanine®, which was developed as a result of its sponsored research program at Western University, based in London, Ontario, Canada. The application of CBD alone has little effect/impact on the ability of the Central Nervous System “CNS” to help with mental health issues. Our newly developed formula will be a “life changer” for many. The scientifically developed formula went through pre-clinical studies at Western University. Results from these pre-clinical trials, addressing anxiety, depression, PTSD, and schizophrenia [...]